Abate AS Industries Limited has scheduled its 35th Annual General Meeting for September 16, 2026. The meeting will be conducted via video conference or other audio-visual means at 3:00 pm.

The company notified the BSE of newspaper advertisements published on August 21, 2026, in compliance with SEBI Listing Regulations and the Companies Act, 2013. The notice outlines procedures for remote e-voting and book closure.

E-Voting and Book Closure Details

The company will facilitate remote e-voting through Central Depository Services (India) Limited. Members can cast their votes during the specified window before the meeting date.

The register of members and share transfer books will remain closed from September 10, 2026, to September 16, 2026, inclusive. Physical attendance is not required, and participants joining via VC/OAVM will count toward the quorum under Section 103 of the Act.

Key Agenda Items

Shareholders will vote on several special resolutions concerning board composition and corporate structure:

• Reappointment of Executive Director: Dr Muhammed Swadique (DIN: 02933064) is proposed for reappointment as Executive Director for a five-year term from August 14, 2026, to August 13, 2031.
• Reappointment of Independent Directors: Ms Julie G Varghese (DIN: 09274826) and Ms Indu Kamala Ravindran (DIN: 09252600) are proposed for reappointment as Independent Directors for second consecutive five-year terms.
• Regularization of Appointment: Mr Aboobaker Vattamkandathil (DIN: 10059868), appointed as Additional Director on August 13, 2026, seeks regularization as a Non-Executive Independent Director.
• Alteration of MOA Object Clause: The company proposes altering Clause III(A)(1) of its Memorandum of Association to comprehensively empower operations in modern healthcare infrastructure, multi-specialty hospital administration, digital health, telemedicine, and allied healthcare services.

Shareholder Instructions

Electronic copies of the AGM notice and annual report for FY26 will be sent to registered email addresses. Shareholders without registered emails will receive a letter with a web link. Physical holders must register their email addresses by sending a signed request with folio numbers and identity proofs to the registrar. Demat holders should update details with their depository participants.

M/s. Lakshmi Subramanian & Associates has been appointed as the scrutinizer for the e-voting process.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE454E01013/14a309ad-6c53-4f0d-8ecc-c10b65554fa4.pdf

Abate As Industries reported a consolidated net profit of ₹224.34 lakh for the quarter ended June 30, 2026, marking a 22% decline from ₹240.93 lakh in the corresponding period of FY25. Total revenue fell sharply by 44% to ₹2,307.29 lakh, down from ₹4,147.91 lakh year-ago, driven primarily by a contraction in revenue from operations which slipped to ₹2,281.82 lakh from ₹4,105.86 lakh.

The company’s standalone entity posted a profit of ₹14.31 lakh against ₹13.46 lakh in Q1FY25, with total revenue recorded at ₹25.05 lakh. The divergence between the modest standalone performance and the significant consolidated headwinds highlights the weight of subsidiary operations on the group’s overall financial health.

Board Approvals and Corporate Actions

During its meeting on August 13, 2026, the board approved the unaudited financial results for both standalone and consolidated entities, subject to limited review by statutory auditors Mahesh C Solanki & Co. The board also scheduled the 35th Annual General Meeting (AGM) for September 16, 2026.

Key personnel changes and strategic approvals included:

• New Appointment: Mr. Aboobaker Vattamkandathil was appointed as an Additional Director in the category of Non-Executive Independent Director, effective August 13, 2026.
• Reappointments: Dr. Muhammed Swadique was reappointed as Executive Director, while Ms. Julie G Varghese and Ms. Indu Kamala Ravindran were reappointed as Independent Directors. All terms are effective from August 14, 2026, or December 28, 2026, respectively, until August/December 2031, subject to member approval at the AGM.
• Strategic Expansion: The board proposed a special resolution to alter Clause III(A)(1) of the Memorandum of Association. This amendment aims to broaden the company’s scope to include establishing, operating, and managing multi-specialty hospitals, diagnostic centers, and digital healthcare platforms, signaling a pivot toward the integrated healthcare sector.

Financial Performance Overview

What the Numbers Show

The consolidated result reveals a significant compression in operational efficiency alongside the revenue drop. While revenue from operations declined by 44%, total expenses decreased by only 17% to ₹2,036.34 lakh from ₹3,915.62 lakh. This disparity indicates that fixed cost structures did not scale down proportionally with the sharp fall in top-line growth, pressuring margins.

Furthermore, tax expenses rose sharply to ₹48.49 lakh in Q1FY26 compared to ₹16.29 lakh in Q1FY25, despite the lower pre-tax profit of ₹272.83 lakh versus ₹240.93 lakh. This suggests a higher effective tax rate or changes in deferred tax provisions impacting the bottom line disproportionately to the earnings decline.